Figure 7.
In vivo hemostatic function of FIXa-WT and FIXa-V16L variants. (A) Tail clip assay was performed on HB mice injected with FIXa-WT or FIXa-V16L (50 μg/kg, n = 3-7) 5 minutes before injury, and blood loss (μL) was collected for 10 minutes. (B) The TVT assay was performed on HB mice injected with FIXa-WT or FIX-V16L (50 μg/kg, n = 7) 30 seconds before injury, and blood loss (μL) was collected for 60 minutes. Data are presented as mean ± SD. Adjusted P values were obtained using an ANOVA test followed by a Tukey test. ∗∗P < .0001 or n.s. represent FIXa-V16L vs FIXa-WT infused animals. (C-D) Graphs showing the median for AUC for CD41 or for fibrin vs time curve in HB mice injected with FIXa-WT or FIXa-V16L (10 μg/kg), or PBS. Each time point represents the median ± SD of 2 to 3 thrombi from 2 to 3 mice. (panels A-D) HB or WT mice infused with PBS served as controls.

In vivo hemostatic function of FIXa-WT and FIXa-V16L variants. (A) Tail clip assay was performed on HB mice injected with FIXa-WT or FIXa-V16L (50 μg/kg, n = 3-7) 5 minutes before injury, and blood loss (μL) was collected for 10 minutes. (B) The TVT assay was performed on HB mice injected with FIXa-WT or FIX-V16L (50 μg/kg, n = 7) 30 seconds before injury, and blood loss (μL) was collected for 60 minutes. Data are presented as mean ± SD. Adjusted P values were obtained using an ANOVA test followed by a Tukey test. ∗∗P < .0001 or n.s. represent FIXa-V16L vs FIXa-WT infused animals. (C-D) Graphs showing the median for AUC for CD41 or for fibrin vs time curve in HB mice injected with FIXa-WT or FIXa-V16L (10 μg/kg), or PBS. Each time point represents the median ± SD of 2 to 3 thrombi from 2 to 3 mice. (panels A-D) HB or WT mice infused with PBS served as controls.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal